✦ LIBER ✦

Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism

✍ Scribed by S. Eichinger; A. Weltermann; E. Minar

Book ID: 113414095
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 38 KB
Volume: 13
Category: Article
ISSN: 1062-1458
DOI: 10.1016/j.accreview.2004.03.085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of Recurrent Venous Thromboembolism

Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients

✍ den Exter, P. L.; Hooijer, J.; Dekkers, O. M.; Huisman, M. V. 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 109 KB

The risk of recurrent venous thromboembo

The risk of recurrent venous thromboembolism: The Austrian Study on Recurrent Venous Thromboembolism

✍ Paul Alexander Kyrle; Sabine Eichinger 📂 Article 📅 2003 🏛 Springer Vienna 🌐 English ⚖ 78 KB

Venous thromboembolism and the risk of s

Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis

✍ P. PRANDONI; A. GHIRARDUZZI; M. H. PRINS; V. PENGO; B. L. DAVIDSON; H. SØRENSEN; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Incidence of recurrent venous thromboemb

Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism

✍ Daniela Poli; Elisa Grifoni; Emilia Antonucci; Chiara Arcangeli; Domenico Prisco 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 194 KB

Use of bisphosphonates and raloxifene an

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

✍ P. Vestergaard; K. Schwartz; E. M. Pinholt; L. Rejnmark; L. Mosekilde 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 147 KB

Predicting the risk of venous thromboemb

Predicting the risk of venous thromboembolism recurrence

✍ John A. Heit 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 867 KB

## Abstract Venous thromboembolism (VTE) is a chronic disease with a 30% ten‐year recurrence rate. The highest incidence of recurrence is in the first 6 months. Active cancer significantly increases the hazard of early recurrence, and the proportions of time on standard heparin with an APTT ≥ 0.2 a